Agenus traded at $2.65 this Friday August 5th, increasing $0.09 or 3.52 percent since the previous trading session. Looking back, over the last four weeks, Agenus gained 9.05 percent. Over the last 12 months, its price fell by 52.93 percent. Looking ahead, we forecast Agenus to be priced at 2.58 by the end of this quarter and at 2.37 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
2.65
Daily Change
3.52%
Yearly
-52.93%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Jiangsu Hengrui Me. 38.09 0.06 0.16% -33.08%
AbbVie 138.04 -0.88 -0.63% 20.61%
Agenus 2.65 0.09 3.52% -52.93%
Amgen 246.25 -0.73 -0.30% 7.00%
AstraZeneca 10,866.00 146.00 1.36% 33.21%
Bristol-Myers Squibb 72.12 0 0% 5.87%
ChemoCentryx 50.52 0.09 0.18% 231.28%
Celldex Therapeutics 36.69 2.29 6.66% -22.92%
CSL 295.64 -1.11 -0.37% -0.41%
Dynavax Technologies 16.65 2.31 16.11% 55.03%
Gilead Sciences 61.09 -0.82 -1.32% -11.18%
Genocea Biosciences 0.01 0.001 5.71% -99.44%
GlaxoSmithKline 1,667.00 8.60 0.52% 16.05%
Glaxosmithkline 40.57 -0.03 -0.07% 0.40%
Immunogen 5.45 0.01 0.18% -4.55%
Incyte Corp 72.16 0.25 0.35% -5.43%
J&J 171.11 -0.68 -0.40% -1.16%
Karyopharm Therapeutics 4.68 0.15 3.31% -15.22%
Eli Lilly 301.32 -4.47 -1.46% 14.38%
MacroGenics 4.39 0.45 11.42% -82.11%
Merck 185.20 0.65 0.35% 2.77%
Merck & Co 87.41 0.59 0.68% 15.87%
Novartis 82.05 0.69 0.85% -1.74%
Novavax 60.27 -1.66 -2.68% -68.26%
Northwest Biotherapeutics 0.67 -0.01 -0.80% -48.46%
Pfizer 49.27 -0.59 -1.18% 9.32%
Regeneron Pharmaceuticals 613.61 -1.35 -0.22% 0.45%
Rigel Pharmaceuticals 1.52 0.08 5.56% -60.11%
Sangamo BioSciences 5.20 0.43 9.01% -46.72%
Veracyte 27.90 0.24 0.87% -40.60%
Intrexon 2.07 -0.05 -2.36% -62.77%

Indexes Price Day Year
USND 12658 -63.03 -0.50% -14.68%
US2000 1922 15.37 0.81% -14.50%

Agenus
Agenus Inc. (Agenus) is a clinical-stage immuno-oncology (I-O) company. It has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, neoantigen cancer vaccines (individualized and off-the shelf) platforms and adjuvants. Its anti-PD-1 antibody and first-generation and next generation anti-CTLA-4 antagonists are in clinical development. Its pipeline of pre-clinical assets, which include AGEN1777, an anti-TIGIT bispecific antibody and AGEN1327, an anti-TIGIT monospecific antibody. Its neoantigen vaccine platforms include its heat shock protein (HSP) based Prophage vaccine candidates and its synthetic, neoantigen vaccine candidates, AutoSynVax (ASV) and PhosphoSynVax (PSV). Its neoantigen vaccine platforms include individualized ASV and off-the-shelf PSV, which target antigens expressed across patients and tumors.